Chemomab Therapeutics Stock (NASDAQ:CMMB)


OwnershipFinancialsChart

Previous Close

$1.65

52W Range

$0.42 - $2.55

50D Avg

$1.55

200D Avg

$1.11

Market Cap

$30.55M

Avg Vol (3M)

$234.96K

Beta

0.30

Div Yield

-

CMMB Company Profile


Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

IL

Employees

20

IPO Date

Feb 12, 2019

Website

CMMB Performance


CMMB Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-25.39M$-28.53M$-12.40M
Net Income$-24.16M$-27.65M$-12.55M
EBITDA$-25.39M$-28.48M$-12.37M
Basic EPS$-2.06$-2.43$-1.21
Diluted EPS$-2.06$-2.43$-1.21

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 23May 14, 23 | 11:20 AM
Q3 22Nov 11, 22 | 12:00 PM
Q2 22Aug 12, 22 | 2:40 PM

Peer Comparison


TickerCompany
SNTISenti Biosciences, Inc.
ZVSAZyVersa Therapeutics, Inc.
BDRXBiodexa Pharmaceuticals Plc
ONCROncorus, Inc.
MNPRMonopar Therapeutics Inc.
LEXXLexaria Bioscience Corp.
SABSSAB Biotherapeutics, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
HILSTharimmune, Inc.
BOLTBolt Biotherapeutics, Inc.
ELDNEledon Pharmaceuticals, Inc.
RNXTRenovoRx, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
NLTXNeurogene Inc.
CLRBCellectar Biosciences, Inc.
LBPHLongboard Pharmaceuticals, Inc.
LUMOLumos Pharma, Inc.